An innate immune signature induced by AS01- or AS03-adjuvanted vaccines predicts the antibody response magnitude and quality consistently over time
Authors:
Open Access
- 14 August 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1412732
Abstract
Background: Antibody-mediated protection can depend on mechanisms varying from neutralization to Fc-dependent innate immune-cell recruitment. Adjuvanted vaccine development relies on a holistic understanding of how adjuvants modulate the quantity/titer and quality of the antibody response.Methods: A Phase 2 trial (ClinicalTrials.gov: NCT00805389) evaluated hepatitis B vaccines formulated with licensed adjuvants (AS01B, AS01E, AS03, AS04 or Alum) in antigen-naïve adults. The trial investigated the role of adjuvants in shaping antibody-effector functions, and identified an innate transcriptional response shared by AS01B, AS01E and AS03. We integrated previously reported data on the innate response (gene expression, cytokine/C-reactive protein levels) and on quantitative/qualitative features of the mature antibody response (Fc-related parameters, immunoglobulin titers, avidity). Associations between the innate and humoral parameters were explored using systems vaccinology and a machine-learning framework.Results: A dichotomy in responses between AS01/AS03 and AS04/Alum (with the former two contributing most to the association with the humoral response) was observed across all timepoints of this longitudinal study. The consistent patterns over time suggested a similarity in the impacts of the two-dose immunization regimen, year-long interval, and non-adjuvanted antigenic challenge given one year later. An innate signature characterized by interferon pathway-related gene expression and secreted interferon-γ-induced protein 10 and C-reactive protein, which was shared by AS01 and AS03, consistently predicted both the qualitative antibody response features and the titers. The signature also predicted from the antibody response quality, the group of adjuvants from which the administered vaccine was derived.Conclusion: An innate signature induced by AS01- or AS03-adjuvanted vaccines predicts the antibody response magnitude and quality consistently over time.Keywords
Funding Information
- GlaxoSmithKline
This publication has 48 references indexed in Scilit:
- Antibody effector functions are associated with protection from respiratory syncytial virusCell, 2022
- The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccinationCell, 2021
- The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2International Journal of Infectious Diseases, 2021
- Association is not prediction: A landscape of confused reporting in diabetes – A systematic reviewDiabetes Research and Clinical Practice, 2020
- The Impact of the Microbiome on Immunity to Vaccination in HumansCell Host & Microbe, 2020
- NK cell immune responses differ after prime and boost vaccinationJournal of Leukocyte Biology, 2019
- Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trialClinical Immunology, 2016
- Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems SerologyCell, 2015
- Systems VaccinologyImmunity, 2010
- Varicella‐zoster virus antibody avidity and IgG‐subclass patterns in children with recurrent chickenpoxJournal of Medical Virology, 1994